XBIOTECH INC. Cash and Cash Equivalents, Period Increase (Decrease)
XBIOTECH INC. (XBIT) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$473.05 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-05-11
- XBIOTECH INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was -$473.05M.
- XBIOTECH INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was $674.26M.
- XBIOTECH INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was -$4.58M.
- XBIOTECH INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $32.90M.
- XBIOTECH INC. cash and cash equivalents, period increase (decrease) for fiscal 2019 was $698.77M.
- XBIOTECH INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$15.95M.
- XBIOTECH INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$2.56M.
- XBIOTECH INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$56.73M, a 268.22% decline from fiscal 2015.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$473.05M 10-Q · filed 2020-05-11 | $201.20M derived: sum of 2 quarters · filed 2020-05-11 | $196.62M derived: sum of 3 quarters · filed 2020-05-11 | $229.52M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-12-31 | $674.26M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $669.67M derived: sum of 2 quarters · filed 2020-03-16 | $702.58M derived: sum of 3 quarters · filed 2020-03-16 | $698.77M 10-K · filed 2020-03-16 |
| 2019-09-30 | -$4.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $28.32M derived: sum of 2 quarters · filed 2019-11-12 | $24.52M 10-Q · filed 2019-11-12 | $19.49M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-06-30 | $32.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $29.10M 10-Q · filed 2019-08-09 | $24.07M derived: sum of 3 quarters · filed 2020-05-11 | $20.07M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-03-31 | -$3.80M 10-Q · filed 2020-05-11 | -$8.83M derived: sum of 2 quarters · filed 2020-05-11 | -$12.83M derived: sum of 3 quarters · filed 2020-05-11 | -$16.40M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | -$5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$9.03M derived: sum of 2 quarters · filed 2020-03-16 | -$12.59M derived: sum of 3 quarters · filed 2020-03-16 | -$15.95M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$7.57M derived: sum of 2 quarters · filed 2019-11-12 | -$10.92M 10-Q · filed 2019-11-12 | -$18.13M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | -$3.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$6.92M 10-Q · filed 2019-08-09 | -$14.13M derived: sum of 3 quarters · filed 2020-03-16 | -$21.10M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | -$3.35M 10-Q · filed 2019-05-09 | -$10.56M derived: sum of 2 quarters · filed 2020-03-16 | -$17.53M derived: sum of 3 quarters · filed 2020-03-16 | -$26.22M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | -$7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$14.18M derived: sum of 2 quarters · filed 2020-03-16 | -$22.86M derived: sum of 3 quarters · filed 2020-03-16 | -$2.56M 10-K · filed 2020-03-16 |
| 2017-09-30 | -$6.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$15.65M derived: sum of 2 quarters · filed 2018-10-31 | $4.65M 10-Q · filed 2018-10-31 | -$7.82M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | -$8.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $11.63M 10-Q · filed 2018-08-09 | -$844.00K derived: sum of 3 quarters · filed 2019-03-15 | -$18.85M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $20.31M 10-Q · filed 2018-05-08 | $7.84M derived: sum of 2 quarters · filed 2019-03-15 | -$10.17M derived: sum of 3 quarters · filed 2019-03-15 | -$23.59M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | -$12.47M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-03-15 | -$30.47M derived: sum of 2 quarters · filed 2019-03-15 | -$43.90M derived: sum of 3 quarters · filed 2019-03-15 | -$56.73M 10-K/A · filed 2019-03-15 |
| 2016-09-30 | -$18.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$31.43M derived: sum of 2 quarters · filed 2017-11-09 | -$44.26M 10-Q · filed 2017-11-09 | -$58.89M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-06-30 | -$13.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$26.25M 10-Q · filed 2017-08-08 | -$40.88M derived: sum of 3 quarters · filed 2018-03-16 | -$52.58M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-03-31 | -$12.83M 10-Q · filed 2017-05-10 | -$27.45M derived: sum of 2 quarters · filed 2018-03-16 | -$39.16M derived: sum of 3 quarters · filed 2018-03-16 | $25.99M derived: sum of 4 quarters · filed 2018-03-16 |
| 2015-12-31 | -$14.63M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$26.33M derived: sum of 2 quarters · filed 2018-03-16 | $38.81M derived: sum of 3 quarters · filed 2018-03-16 | $33.72M 10-K · filed 2018-03-16 |
| 2015-09-30 | -$11.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $53.44M derived: sum of 2 quarters · filed 2016-11-14 | $48.35M 10-Q · filed 2016-11-14 | $90.18M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $65.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-12 | $60.05M 10-Q · filed 2016-08-12 | $101.89M derived: sum of 3 quarters · filed 2017-03-16 | $103.97M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | -$5.09M 10-Q · filed 2016-05-13 | $36.74M derived: sum of 2 quarters · filed 2017-03-16 | $38.83M derived: sum of 3 quarters · filed 2017-03-16 | $35.87M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $41.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $43.92M derived: sum of 2 quarters · filed 2017-03-16 | $40.96M derived: sum of 3 quarters · filed 2017-03-16 | $50.09M 10-K · filed 2017-03-16 |
| 2014-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$870.00K derived: sum of 2 quarters · filed 2015-11-13 | $8.25M 10-Q · filed 2015-11-13 | |
| 2014-06-30 | -$2.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $6.17M 10-Q · filed 2015-08-14 | ||
| 2014-03-31 | $9.12M 10-Q · filed 2015-06-18 | |||
| 2013-12-31 | $3.08M 10-K · filed 2016-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |